Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THN102 in Sleep Deprivation
NCT03182413Phase 1Completed
- Sponsor
- Theranexus
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of THN102 in narcolepsy and Parkinson's disease (PD) (5 arms), sponsored by Theranexus. Primary endpoint: Sustained attention (Psychomotor Vigilance Task). Started Sep 2015; status: completed.
02
Drugs
THN102
03
Conditions
narcolepsyParkinson's disease (PD)
Beyond the preview
Go deeper on NCT03182413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182413.